SUPERNUS PHARMACEUTICALS, INC.

Supernus Pharmaceuticals, Inc. held a special meeting of its stockholders on October 15, 2026, where the adoption of the Merger Agreement with Indivior Pharmaceuticals Inc. and Artemis Merger Sub, Inc. was overwhelmingly approved. The merger will result in Supernus becoming a wholly-owned subsidiary of Indivior. Stockholders also approved, on a non-binding basis, the compensation for named executive officers in connection with the Merger.

Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals Inc. announced a proposed merger of equals to create a diversified CNS biopharmaceutical leader. The transaction is structured as a 100% tax-free stock-for-stock merger, with Supernus shareholders receiving 1.5401 Indivior shares per Supernus share. Indivior will also declare a $1 billion dividend to its pre-closing stockholders. The combined entity, named Supernus, Inc., anticipates annual cost synergies of at least $125 million and targets closing in Q4 2026.

Supernus Pharmaceuticals reported a net loss of $(58.37) million for Q2 2026, a significant decline from net earnings of $22.50 million in Q2 2025, primarily due to a $54.92 million intangible asset impairment charge. Despite the loss, total revenues grew by 32.4% to $219.06 million, driven by new collaboration revenue from ZURZUVAE and increased net product sales. Basic EPS for the quarter was $(1.01).

Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals Inc. have entered into a definitive agreement for an all-stock merger of equals. The combined entity, to be named Supernus, Inc., will create a diversified CNS biopharmaceutical leader with significant scale, trading on Nasdaq under the ticker "SUPN". Supernus stockholders will receive 1.5401 shares of Indivior for each Supernus share, resulting in Indivior stockholders owning approximately 56.5% and Supernus stockholders 43.5% of the combined company. The transaction is expected to generate $2.2 billion in pro forma net revenue, $888 million in pro forma adjusted EBITDA, and $125 million in annual cost synergies. Indivior will also issue a $1.0 billion special cash dividend to its stockholders, partially financed by a $650 million term loan.

Supernus Pharmaceuticals announced a definitive agreement to combine with Indivior Pharmaceuticals, Inc. in an all-stock merger of equals, creating a diversified CNS biopharmaceutical company. Concurrently, Supernus reported strong second-quarter 2026 financial results, with total revenues increasing 32% to $219.1 million, driven by its four growth products. Despite the revenue growth, the company reported a net loss of $58.4 million due to a $54.9 million intangible asset impairment charge. Supernus also raised its full-year 2026 financial guidance.

Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a definitive agreement to combine in a tax-free all-stock merger of equals. The combined entity, to be named Supernus, Inc., will create a leading diversified CNS biopharmaceutical company with approximately $2.2 billion in combined annual revenues and $888 million in pro forma adjusted EBITDA. The transaction is expected to generate $125 million in annual cost synergies and close in Q4 2026, with Jack Khattar serving as President and CEO.

Supernus Pharmaceuticals, Inc. announced it will report its second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. E.T. to discuss these results. CEO Jack Khattar and CFO Tim Dec will lead the discussion, with a replay available on the company's investor relations website.

Supernus Pharmaceuticals, Inc. announced it will report its second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026. Following the release, President and CEO Jack Khattar and Senior Vice President and CFO Tim Dec will host a conference call and webcast at 4:30 p.m. ET to discuss the results. A live webcast will be available on the company's Investor Relations website, with a replay accessible for 60 days.

Supernus Pharmaceuticals is celebrating the five-year anniversary of the U.S. FDA approval of Qelbree (viloxazine extended-release capsules) for attention-deficit/hyperactivity disorder (ADHD). Since its initial approval for pediatric ADHD in April 2021 and subsequent approval for adults in April 2022, Qelbree has seen approximately 3 million prescriptions filled, with over 1 million in 2025 alone. The company highlights Qelbree's differentiated approach as the first novel, non-stimulant ADHD medication in over a decade, offering 24-hour exposure and no evidence of abuse potential.

Supernus Pharmaceuticals, Inc. held its Annual Meeting of Stockholders on June 18, 2026. Stockholders elected Frederick M. Hudson and Charles W. Newhall, III as Class I Directors. They also approved, on a non-binding basis, the compensation paid to named executive officers and ratified KPMG LLP as the independent public accounting firm for 2026. Additionally, a proposal to amend the 2021 Equity Incentive Plan to increase available shares was approved.